Catalog No.
YXX14901
Expression system
E. coli
Species
Neisseria meningitidis
Protein length
Ser2-Gln254
Predicted molecular weight
27.92 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
AAR84453.1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Factor H binding protein variant A18_001, fhbp, Factor H binding protein variant A18_002, Factor H binding protein variant A18_003
Genetic and Antigenic Diversity of Neisseria meningitidis Serogroup B Strains in Vietnam., PMID:40430807
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine., PMID:40333993
Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection., PMID:40308602
Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013-2020., PMID:40163976
Molecular and WGS-based characterization of invasive Neisseria meningitidis isolates collected in Belgium (2016-2022) and MenB-FHbp vaccine coverage estimation of serogroup B., PMID:40132319
Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial., PMID:39993937
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens., PMID:39983538
The Neisseria meningitidis urethritis clade (NmUC) acts as a "chimeric pathogen" during infection of primary, human male, urethral epithelial cells., PMID:39657012
NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae., PMID:39557897
Exploring the sequence diversity and surface expression of Factor H-Binding Protein among invasive serogroup B meningococcal strains from selected European countries., PMID:39536321
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose., PMID:39520893
Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups., PMID:39387286
Characterisation and Immunogenicity of Neisseria cinerea outer membrane vesicles displaying NadA, NHBA and fHbp from Neisseria meningitidis serogroup B., PMID:39380985
Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction., PMID:39276620
Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review., PMID:39263919
Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H., PMID:39114449
Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014., PMID:39037011
4CMenB journey to the 10-year anniversary and beyond., PMID:38976659
Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine., PMID:38775152
Extensive Genetic Diversity and Epidemiological Patterns of Factor H-Binding Protein Variants among Neisseria meningitidis in China., PMID:38543533
Immune interface interference vaccines: An evolution-informed approach to anti-bacterial vaccine design., PMID:38536702
Bacterial hemophilin homologs and their specific type eleven secretor proteins have conserved roles in heme capture and are diversifying as a family., PMID:38506530
Epitope Mapping of Human Polyclonal Antibodies to the fHbp Antigen of a Neisseria Meningitidis Vaccine by Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS)., PMID:38342408
Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis., PMID:38132917
Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB)., PMID:38111094
Commensal Neisseria cinerea outer membrane vesicles as a platform for the delivery of meningococcal and gonococcal antigens to the immune system., PMID:38008665
Molecular characteristics of Neisseria meningitidis carriage strains in university students in Lithuania., PMID:37978423
Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness., PMID:37622470
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial., PMID:37579773
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway., PMID:37457736
Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review., PMID:37428339
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease., PMID:37343082
Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data., PMID:37316234
Hypervirulent Strains of Neisseria meningitidis and Clinical Manifestations in Children With Invasive Meningococcal Disease., PMID:37267065
Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults., PMID:37257838
Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp., PMID:37024411
Meningococcal factor H-binding protein: implications for disease susceptibility, virulence, and vaccines., PMID:36941192
Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020)., PMID:36913385
Healthy Vaccinee Bias and MenB-FHbp Vaccine Effectiveness Against Gonorrhea., PMID:36863060
FHbp variants among meningococci of serogroup B in Italy: Evolution and selective pressure, 2014-2017., PMID:36795654
Genomic characterization of invasive meningococcal X isolates from Brazil, 1992-2022., PMID:36626096
Whole genome sequence analysis of Neisseria meningitidis strains circulating in Kazakhstan, 2017-2018., PMID:36576937
Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines., PMID:36129279
Self-assembling protein nanoparticles and virus like particles correctly display β-barrel from meningococcal factor H-binding protein through genetic fusion., PMID:36112575
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies., PMID:36087588
Investigating the Role of Antigen Orientation on the Immune Response Elicited by Neisseria meningitidis Factor H Binding Protein on GMMA., PMID:35893831
Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients., PMID:35803542
Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage., PMID:35778280
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine., PMID:35257644
Product review on the IMD serogroup B vaccine Bexsero®., PMID:35192786
For research use only. Not for human or drug use.
